Company intelligence / Profile preview

Hangzhou Jiayin Biotech

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Hangzhou Jiayin Biotech is a clinical-stage biotech company specializing in advanced gene therapies using adeno-associated virus (AAV) and lentiviral vectors. Its lead program EXG001-307 is being evaluated in multiple Phase 1/2 trials for spinal muscular atrophy type I. Another program EXG102‑031 has received IND approval for wet age-related macular degeneration. The company has established GMP manufacturing capabilities up to commercial scale.

Therapeutic areas: OphthalmologyHematologyNeurology
Modalities: Gene therapyAAV-based gene therapylentivirus-based gene therapy
Industry: Biotech

Beyond the preview

Go deeper on Hangzhou Jiayin Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Jiayin Biotech.

Explore the full profile